316 related articles for article (PubMed ID: 27029727)
41. Risks of PSA screening now better understood.
Peres J
J Natl Cancer Inst; 2013 Nov; 105(21):1590-2. PubMed ID: 24142893
[No Abstract] [Full Text] [Related]
42. Screening for Prostate Cancer-Beyond Total PSA, Utilization of Novel Biomarkers.
Morgan T; Palapattu G; Wei J
Curr Urol Rep; 2015 Sep; 16(9):63. PubMed ID: 26169584
[TBL] [Abstract][Full Text] [Related]
43. Improving the Specificity of PSA Screening with Serum and Urine Markers.
Kearns JT; Lin DW
Curr Urol Rep; 2018 Aug; 19(10):80. PubMed ID: 30105509
[TBL] [Abstract][Full Text] [Related]
44. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.
Otto SJ; Moss SM; Määttänen L; Roobol M; Zappa M; Nelen V; Kwiatkowski M; Villers A; Hugosson J; Sanchez AB; de Koning HJ
Eur J Cancer; 2010 Nov; 46(17):3053-60. PubMed ID: 21047586
[TBL] [Abstract][Full Text] [Related]
45. Prostate specific antigen. Current clinical application and future prospects.
Duskova K; Vesely S
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Mar; 159(1):18-26. PubMed ID: 25277491
[TBL] [Abstract][Full Text] [Related]
46. Diagnostic performance of expression of PCA3, Hepsin and miR biomarkers inejaculate in combination with serum PSA for the detection of prostate cancer.
Roberts MJ; Chow CW; Schirra HJ; Richards R; Buck M; Selth LA; Doi SA; Samaratunga H; Perry-Keene J; Payton D; Yaxley J; Lavin MF; Gardiner RA
Prostate; 2015 Apr; 75(5):539-49. PubMed ID: 25597828
[TBL] [Abstract][Full Text] [Related]
47. Biomarkers for early prostate cancer detection.
Margreiter M; Stangelberger A; Valimberti E; Herwig R; Djavan B
Minerva Urol Nefrol; 2008 Mar; 60(1):51-60. PubMed ID: 18427435
[TBL] [Abstract][Full Text] [Related]
48. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
49. Prostate-specific antigen-based population screening for prostate cancer: current status in Japan and future perspective in Asia.
Kitagawa Y; Namiki M
Asian J Androl; 2015; 17(3):475-80. PubMed ID: 25578935
[TBL] [Abstract][Full Text] [Related]
50. New biomarkers for diagnosis and prognosis of localized prostate cancer.
Chistiakov DA; Myasoedova VA; Grechko AV; Melnichenko AA; Orekhov AN
Semin Cancer Biol; 2018 Oct; 52(Pt 1):9-16. PubMed ID: 29360504
[TBL] [Abstract][Full Text] [Related]
51. Beyond the PSA test: How to better stratify a patient's risk of prostate cancer.
Lewis R; Hornberger B
JAAPA; 2017 Aug; 30(8):51-54. PubMed ID: 28742748
[TBL] [Abstract][Full Text] [Related]
52. Biomarkers in localized prostate cancer.
Ferro M; Buonerba C; Terracciano D; Lucarelli G; Cosimato V; Bottero D; Deliu VM; Ditonno P; Perdonà S; Autorino R; Coman I; De Placido S; Di Lorenzo G; De Cobelli O
Future Oncol; 2016 Feb; 12(3):399-411. PubMed ID: 26768791
[TBL] [Abstract][Full Text] [Related]
53. Assays for prostate cancer : changing the screening paradigm?
Hansen J; Rink M; Graefen M; Shariat S; Chun FK
Mol Diagn Ther; 2013 Feb; 17(1):1-8. PubMed ID: 23355098
[TBL] [Abstract][Full Text] [Related]
54. Re: The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.
Taneja SS
J Urol; 2015 Jan; 193(1):127. PubMed ID: 25523657
[No Abstract] [Full Text] [Related]
55. [Screening for prostate cancer using prostate-specific antigen (PSA) : A commentary on a systematic review and meta-analysis].
Borkowetz A
Urologe A; 2019 Aug; 58(8):925-928. PubMed ID: 31240375
[No Abstract] [Full Text] [Related]
56. Screening for prostate cancer: moving forward in the molecular era.
Vlachaki A; Baltogiannis D; Batistatou A; Tsambalas S; V Simos Y; E Palatianou M; Vezyraki P; Ragos V; Tsiambas E; Giannakopoulos X; Peschos D
J BUON; 2018; 23(5):1242-1248. PubMed ID: 30570843
[TBL] [Abstract][Full Text] [Related]
57. Response to the U.S. Preventative Services Task Force decision on prostate cancer screening.
Makovey I; Stephenson AJ; Haywood S
Curr Urol Rep; 2013 Jun; 14(3):168-73. PubMed ID: 23568623
[TBL] [Abstract][Full Text] [Related]
58. The Case for Tailored Prostate Cancer Screening: An NCCN Perspective.
McDonald ML; Parsons JK
J Natl Compr Canc Netw; 2015 Dec; 13(12):1576-83. PubMed ID: 26656524
[TBL] [Abstract][Full Text] [Related]
59. Prostate cancer: PSA velocity in prostate cancer screening--the debate continues.
Borofsky MS; Makarov DV
Nat Rev Urol; 2011 Jul; 8(8):413-4. PubMed ID: 21750502
[No Abstract] [Full Text] [Related]
60. PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer.
Tosoian J; Loeb S
ScientificWorldJournal; 2010 Oct; 10():1919-31. PubMed ID: 20890581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
